Investor Presentaiton

ONENESS Outcomes in Two Exploratory Studies in AD Mean EASI Score 30 FB825 25 20 20 26.4 26.0 Reconfirmed Clinical Efficacy Changes in EASI Score 15.9 15 10 10 5 12.0 10.6 13.8 IIS with 12 moderate-to-severe AD patients (q12w) and BM study with 20 moderate-to-severe AD patients (1 dose) The change in EASI score has been similar in two studies 11.0 8.4 1 15 29 43 57 Day IIS BM Study | 19

View entire presentation